-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort --
-- No New Safety Signals or Added Systemic Safety Concerns Observed --
-- Data Presented at the European Society for Medical Oncology (ESMO) Congress --
Sept. 14, 2024 -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, ann